DEBRA Research and LEO Pharma Form Strategic Partnership for Rare Skin Diseases

DEBRA Research GmbH and LEO Pharma have announced a strategic partnership. This collaboration aims to expand research and develop treatments for Epidermolysis Bullosa (EB), a rare genetic skin condition. With no current approved treatments, the partnership seeks to address the unmet needs of EB patients.

This non-exclusive partnership combines DEBRA's focus on patient care with LEO Pharma's expertise in medical dermatology. The goal is to accelerate the creation of transformative therapies for EB. Prof. Hubert Truebel of DEBRA highlights the opportunity to combine resources and drive advancements in treating this challenging condition.

Dr. Jacob Pontoppidan Thyssen, LEO Pharma’s Chief Scientific Officer, emphasizes the importance of developing treatment solutions for high unmet needs, highlighting the partnership's potential to make a significant difference for EB patients.